<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002630</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000064030</org_study_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>928003</secondary_id>
    <secondary_id>V95-0613</secondary_id>
    <nct_id>NCT00002630</nct_id>
  </id_info>
  <brief_title>High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse</brief_title>
  <official_title>HIGH-DOSE MELPHALAN CHEMOTHERAPY AND TOTAL BODY RADIATION WITH PERIPHERAL BLOOD STEM-CELL RECONSTITUTION FOR PATIENTS WITH RELAPSING MULTIPLE MYELOMA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
      Combining peripheral stem cell transplantation with chemotherapy and radiation therapy may
      allow the doctor to give higher doses of radiation and chemotherapy drugs and kill more tumor
      cells.

      PURPOSE: Phase II trial to study the effectiveness of high-dose melphalan plus total-body
      irradiation and peripheral stem cell transplantation in treating patients with multiple
      myeloma in first relapse.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Assess bone marrow reconstitution and peripheral blood cell counts of patients
      with multiple myeloma treated with high-dose melphalan (L-PAM) and total-body irradiation
      (TBI) followed by peripheral blood stem cell (PBSC) rescue. II. Assess the efficacy of
      intravenous L-PAM and TBI for treatment of relapsing/refractory myeloma. III. Assess the
      tolerability and toxicity of this regimen in patients with relapsing multiple myeloma. IV.
      Assess response rate and survival of relapsing/refractory patients treated with this regimen.

      OUTLINE: Prior to entry, patients will have received 3 monthly courses of standard VAD
      followed by PBSC collection on Regimen A; those who responded to VAD continue standard VAD to
      best response and upon relapse (on or off therapy) proceed to Regimen B. Patients with no
      response to 3 courses of VAD and those with no response to an alkylating-based regimen
      proceed immediately to Regimen B following PBSC collection. The following acronyms are used:
      CTX Cyclophosphamide, NSC-26271 G-CSF Granulocyte Colony Stimulating Factor (Amgen),
      NSC-614629 L-PAM Melphalan, NSC-8806 PBSC Peripheral Blood Stem Cells VAD
      Vincristine/Doxorubicin/Dexamethasone TBI Total Body Irradiation Regimen A: Stem Cell
      Mobilization/Harvest. CTX; G-CSF. Regimen B: Single-Agent Myeloablative Chemoradiotherapy
      with Stem Cell Rescue. L-PAM; TBI (Co60 or linear accelerators of 4 MV or greater); with
      PBSC.

      PROJECTED ACCRUAL: If 9 or fewer or 20 or more responses are seen in the first 50 patients
      treated, the study will be discontinued.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1993</start_date>
  <completion_date type="Actual">May 2001</completion_date>
  <primary_completion_date type="Actual">February 1999</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>low-LET cobalt-60 gamma ray therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>low-LET photon therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Multiple myeloma confirmed by bone marrow plasmacytosis and with
        measurable M-component in the serum or urine by immunoelectrophoresis or immunofixation No
        Stage I myeloma No smoldering multiple myeloma Refractory to or in first relapse following
        an initial response to VAD (vincristine/doxorubicin/dexamethasone), with relapse defined as
        any of the following: 50% increase above the lowest remission level of serum or urine
        M-protein while on therapy 25-50% increase above the lowest remission level of serum or
        urine M-protein associated with either: Hypercalcemia (greater than 11 mg/dl) Hb decrease
        of 2 g/dl attributable to increasing marrow plasmacytosis Appearance of new lytic lesions
        Calcium no greater than 11 mg/dl No myeloma meningitis No plasma cell leukemia

        PATIENT CHARACTERISTICS: Age: 18 to 65 Performance status: ECOG 0-2 Hematopoietic: WBC
        greater than 500 (after G-CSF) Platelets greater than 25,000 Hepatic: Bilirubin no greater
        than 2.0 mg/dl Renal: Creatinine no greater than 2.0 mg/dl Cardiovascular: No NYHA class
        II-IV disease Pulmonary: DLCO at least 50% of predicted FVC at least 75% of predicted FEV1
        at least 60% of predicted Other: No uncontrolled infection No active fungal infection No
        fever No prior malignancy within 5 years except: Basal cell skin cancer In situ carcinoma
        of the cervix No pregnant or nursing women

        PRIOR CONCURRENT THERAPY: Biologic therapy: Prior biological response modifiers allowed
        Chemotherapy: No time limit between cytotoxic therapy and protocol treatment Prior
        cumulative melphalan dose less than 300 mg Endocrine therapy: Corticosteroids for
        hypercalcemia allowed Radiotherapy: Prior radiotherapy allowed Prior pelvic radiotherapy
        allowed, but patients with such therapy are unlikely to have adequate PBSC harvested
        Surgery: Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Morie A. Gertz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Porrata LF, Gertz MA, Inwards DJ, Litzow MR, Lacy MQ, Tefferi A, Gastineau DA, Dispenzieri A, Ansell SM, Micallef IN, Geyer SM, Markovic SN. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood. 2001 Aug 1;98(3):579-85.</citation>
    <PMID>11468153</PMID>
  </reference>
  <reference>
    <citation>Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Witzig TE, Lust JA, Larson D, Therneau TM, Kyle RA, Litzow MR, Greipp PR, Gertz MA. Effect of complete response on outcome following autologous stem cell transplantation for myeloma. Bone Marrow Transplant. 2000 Nov;26(9):979-83.</citation>
    <PMID>11100277</PMID>
  </reference>
  <results_reference>
    <citation>Gertz MA, Lacy MQ, Inwards DJ, Gastineau DA, Tefferi A, Chen MG, Witzig TE, Greipp PR, Litzow MR. Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma. Bone Marrow Transplant. 2000 Jul;26(1):45-50.</citation>
    <PMID>10918404</PMID>
  </results_reference>
  <results_reference>
    <citation>Gertz MA, Lacy MQ, Inwards DJ, Chen MG, Pineda AA, Gastineau DA, Greipp PR, Lust JA, Tefferi A, Witzig TE, Kyle RA, Litzow MR. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma. Bone Marrow Transplant. 1999 Feb;23(3):221-6.</citation>
    <PMID>10084252</PMID>
  </results_reference>
  <results_reference>
    <citation>Rajkumar S, Fonseca R, Lacy M, Witzig T, Lust J, Greipp P, Therneau T, Kyle R, Litzow M, Gertz M. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma. Bone Marrow Transplant. 1999 Sep;24(5):497-503.</citation>
    <PMID>10482933</PMID>
  </results_reference>
  <results_reference>
    <citation>Rajkumar SV, Fonseca R, Dewald GW, Therneau TM, Lacy MQ, Kyle RA, Greipp PR, Gertz MA. Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. Cancer Genet Cytogenet. 1999 Aug;113(1):73-7.</citation>
    <PMID>10459351</PMID>
  </results_reference>
  <results_reference>
    <citation>Rajkumar SV, Fonseca R, Lacy MQ, Witzig TE, Lust JA, Greipp PR, Therneau TM, Kyle RA, Litzow MR, Gertz MA. Autologous stem cell transplantation for relapsed and primary refractory myeloma. Bone Marrow Transplant. 1999 Jun;23(12):1267-72.</citation>
    <PMID>10414914</PMID>
  </results_reference>
  <results_reference>
    <citation>Rajkumar SV, Fonseca R, Lacy MQ, Witzig TE, Lust JA, Greipp PR, Therneau TM, Kyle RA, Litzow MR, Gertz MA. Beta2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma. Bone Marrow Transplant. 1999 Jun;23(12):1261-6.</citation>
    <PMID>10414913</PMID>
  </results_reference>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>July 28, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2004</study_first_posted>
  <last_update_submitted>May 10, 2011</last_update_submitted>
  <last_update_submitted_qc>May 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Morie Gertz, M.D.</name_title>
    <organization>Mayo Clinic Cancer Center</organization>
  </responsible_party>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

